Rhabdomyolysis happened after the start of dabigatran etexilate treatment: A case report

J Musculoskelet Neuronal Interact. 2022 Jun 1;22(2):296-300.

Abstract

There are few reports of rhabdomyolysis caused by anticoagulants, and it is extremely rare for it to be caused by dabigatran etexilate. An 86-year-old female experienced sudden muscle weakness and pain, a significant increase in Creatine kinase, and renal impairment after oral administration of dabigatran etexilate for 3 weeks. The enhanced thigh MRI showed abnormal signal in multiple thigh muscle groups, indicating that the lesions should be considered inflammatory diseases. In conclusion, the possibility of rhabdomyolysis should be ruled out when muscle weakness and myalgia occur at the beginning of dabigatran etexilate treatment.

Keywords: Dabigatran Etexilate; MRI; Muscle Weakness; Myalgia; Rhabdomyolysis.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged, 80 and over
  • Benzimidazoles / adverse effects
  • Dabigatran* / adverse effects
  • Female
  • Humans
  • Muscle Weakness
  • Pyridines / adverse effects
  • Rhabdomyolysis* / chemically induced
  • Rhabdomyolysis* / diagnostic imaging

Substances

  • Benzimidazoles
  • Pyridines
  • Dabigatran